Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Sun Yat-sen University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07255612CT.gov Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer) | — | Not Yet Recruiting | — | — | — |
NCT07406542CT.gov A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07461454CT.gov YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT06875128CT.gov Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease | — | Recruiting | — | — | — |
NCT07333937CT.gov Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07007559CT.gov ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer | — | Recruiting | — | — | — |
NCT06957886CT.gov A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT06889688CT.gov Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06731153CT.gov JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC | — | Not Yet Recruiting | — | — | — |
NCT06102824CT.gov Organoid-based Functional Precision Therapy for Advanced Breast Cancer | — | Recruiting | — | — | — |
Show 63 more trialsShow fewer
NCT06449222CT.gov Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT06383767CT.gov A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT06308939CT.gov Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial | — | Not Yet Recruiting | — | — | — |
NCT05458674CT.gov Tucatinib+Trastuzumab+Eribulin in HER2+ MBC | — | Recruiting | — | — | — |
NCT06268652CT.gov Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer | — | Recruiting | — | — | — |
NCT06081959CT.gov Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT06857305CT.gov Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial | — | Enrolling By Invitation | — | — | — |
NCT05814354CT.gov SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial | — | Recruiting | — | — | — |
NCT05810870CT.gov PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin | — | Active Not Recruiting | — | — | — |
NCT05774886CT.gov Implantable Microdevice for TNBC - Pilot Study | — | Withdrawn | — | — | — |
NCT05953909CT.gov A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01). | — | Unknown | — | — | — |
NCT05238831CT.gov SMMART Adaptive Clinical Treatment (ACT) Trial | — | Withdrawn | — | — | — |
NCT05570253CT.gov A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer | — | Recruiting | — | — | — |
NCT04826016CT.gov POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer | — | Withdrawn | — | — | — |
NCT05104866CT.gov A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | — | Active Not Recruiting | — | — | — |
NCT04986579CT.gov Scalp Cooling in MBC | — | Recruiting | — | — | — |
NCT05346861CT.gov Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab | — | Unknown | — | — | — |
NCT05063786CT.gov Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) | — | Active Not Recruiting | — | — | — |
NCT05033769CT.gov Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer | — | Unknown | — | — | — |
NCT04683445CT.gov Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer | — | Unknown | — | — | — |
NCT04517292CT.gov Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC) | — | Unknown | — | — | — |
NCT04681911CT.gov Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT04303741CT.gov A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC | — | Unknown | — | — | — |
NCT03786094CT.gov Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT03901339CT.gov Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer | — | Completed | — | — | — |
NCT03795012CT.gov Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients | — | Terminated | — | — | — |
NCT03637868CT.gov Eribulin in Brain Metastases From HER2-negative Breast Cancer | — | Withdrawn | — | — | — |
NCT03734029CT.gov Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | — | Active Not Recruiting | — | — | — |
NCT03424005CT.gov A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT03393741CT.gov Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy | — | Terminated | — | — | — |
NCT03222856CT.gov Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes | — | Completed | — | — | — |
NCT02574455CT.gov Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) | — | Completed | — | — | — |
NCT03032614CT.gov Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients | — | Withdrawn | — | — | — |
NCT03264547CT.gov A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab | — | Completed | — | — | — |
NCT02915744CT.gov A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine | — | Completed | — | — | — |
NCT03027245CT.gov Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy | — | Completed | — | — | — |
NCT02723877CT.gov PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO) | — | Completed | — | — | — |
NCT02681523CT.gov ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer. | — | Terminated | — | — | — |
NCT02344472CT.gov Detect V / CHEVENDO (Chemo vs. Endo) | — | Active Not Recruiting | — | — | — |
NCT02551263CT.gov Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02396433CT.gov Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers | — | Withdrawn | — | — | — |
NCT02263495CT.gov Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02215876CT.gov Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer | — | Withdrawn | — | — | — |
NCT02175446CT.gov Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients | — | Unknown | — | — | — |
NCT02299999CT.gov SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02000596CT.gov 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over. | — | Terminated | — | — | — |
NCT02014337CT.gov Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | — | Completed | — | — | — |
NCT01941407CT.gov First Line Metastatic Breast Cancer Treatment (ESMERALDA) | — | Completed | — | — | — |
NCT01912963CT.gov Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer | — | Terminated | — | — | — |
NCT01827787CT.gov Eribulin in HER2 Negative Metastatic BrCa | — | Completed | — | — | — |
NCT01795586CT.gov A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients | — | Completed | — | — | — |
NCT01802970CT.gov Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients | — | Completed | — | — | — |
NCT01705691CT.gov Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer | — | Completed | — | — | — |
NCT01593020CT.gov Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 | — | Completed | — | — | — |
NCT01669252CT.gov Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer | — | Completed | — | — | — |
NCT01596751CT.gov Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01554371CT.gov Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies | — | Completed | — | — | — |
NCT01534455CT.gov Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA) | — | Terminated | — | — | — |
NCT01492101CT.gov The BEACON Study (Breast Cancer Outcomes With NKTR-102) | — | Completed | — | — | — |
NCT01498588CT.gov Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer | — | Terminated | — | — | — |
NCT01427933CT.gov A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer | — | Completed | — | — | — |
NCT01401959CT.gov Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy | — | Completed | — | — | — |
NCT01156753CT.gov A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Eribulin (this asset) | Sun Yat-sen University | Approved | BB · 69 |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Vitamin D | University of Illinois at Chicago | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Tamoxifen | Dana-Farber Cancer Institute | P4 | BB |
| Adriamycin | George Washington University | P4 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Peg-Rhg-Csf | The First Affiliated Hospital with Nanjing Medical University | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Eribulin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Neoplasm | — | P4 | B · 62 |
| Non-Small Cell Lung Carcinoma | — | P3 | B · 62 |
| Breast Carcinoma | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Eribulin in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/eribulin-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →